Overview investors

Uniting our strengths with our investors' to deliver superior, long-term shareholder value

Our Investor Relations team strives to offer a first class service to UCB's current shareholders, potential investors and the financial investment community as a whole.

UCB has the potential to become the next generation biopharma leader

Powerful and unique combination of biology and chemistry research capabilities
12 large and small molecules in clinical development, spanning 16 different types of diseases
A track record of turning novel ideas into therapeutic and commercial realities
Solid product life-cycle management